Global Multiple Myeloma Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2023 to 2030

Description

List of Tables

Multiple myeloma is a blood cancer similar to leukaemia and lymphoma that develops in the bone marrow. Certain white blood cells (WBCs) begin to grow inappropriately within the bone marrow in multiple myeloma. Different treatments are effective in delaying the disease's progression. Induction therapy is the first treatment for the condition. After that, stem cell transplantation (SCT) is performed. In stem cell transplantation, a machine extracts the patient's stem cells, which are then frozen and stored. Following that, the cells are implanted into the patient's body. Patients are also given chemotherapy, which includes administering medications like Adriamycin, Alkeran, Cytoxan, Oncovin, Pomalyst, Revlimid, Thalomid, and Velcade. Proteasome inhibitors are a common treatment for multiple myeloma and are used at all stages of the disease.

Market Dynamics:

The market for multiple myeloma medicines is predicted to develop as the disease's prevalence among the population rises. In addition, the growing elderly population across the globe will surely boost the market for multiple myeloma medicines. Furthermore, the market is expected to rise substantially due to the approval of newer treatments and the low efficacy of the currently available drugs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of multiple myeloma therapeutics. The growth and trends of multiple myeloma therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the multiple myeloma therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

Chemotherapy
Radiation
Stem Cell Transplant
Other Supportive Treatments

By End Users/Applications

Hospitals
Clinics
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Multiple Myeloma Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the multiple myeloma therapeutics market include Janssen Biotech, Inc., Bristol-Myers Squibb, Novartis AG, Bristol-Myers Squibb Company, Millennium Pharmaceuticals, Celgene Corporation, Kesios Therapeutics Limited, Amgene, Inc., Genzyme Corporation, Juno Therapeutics. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR11216795

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . MULTIPLE MYELOMA THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 By Product Type
- 3.7.2 By End Users
- 3.7.3 By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY PRODUCT TYPE

6.1 Overview by Product Type
6.2 Historical and Forecast Data
6.3 Analysis by Product Type
6.4 Chemotherapy Market by Regions
6.6 Radiation Market by Regions
6.5 Stem Cell Transplant Market by Regions
6.7 Other Supportive Treatments Market by Regions

7 . GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY END USERS

7.1 Overview by End Users
7.2 Historical and Forecast Data
7.3 Analysis by End Users
7.4 Hospitals Market by Regions
7.5 Clinics Market by Regions
7.6 Others Market by Regions

8 . GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America
- 8.3.1. Overview, Historic and Forecast Data
- 8.3.2. North America By Segment
- 8.3.3. North America By Country
- 8.3.4. United State
- 8.3.5. Canada
- 8.3.6. Mexico
8.4. Europe
- 8.4.1. Overview, Historic and Forecast Data
- 8.4.2. Europe by Segment
- 8.4.3. Europe by Country
- 8.4.4. United Kingdom
- 8.4.5. France
- 8.4.6. Germany
- 8.4.7. Italy
- 8.4.8. Russia
- 8.4.9. Rest Of Europe
8.5. Asia Pacific
- 8.5.1. Overview, Historic and Forecast Data
- 8.5.2. Asia Pacific by Segment
- 8.5.3. Asia Pacific by Country
- 8.5.4. China
- 8.5.5. India
- 8.5.6. Japan
- 8.5.7. South Korea
- 8.5.8. Australia
- 8.5.9. Rest Of Asia Pacific
8.6. Latin America
- 8.6.1. Overview, Historic and Forecast Data
- 8.6.2. Latin America by Segment
- 8.6.3. Latin America by Country
- 8.6.4. Brazil
- 8.6.5. Argentina
- 8.6.6. Peru
- 8.6.7. Chile
- 8.6.8. Rest of Latin America
8.7. Middle East & Africa
- 8.7.1. Overview, Historic and Forecast Data
- 8.7.2. Middle East & Africa by Segment
- 8.7.3. Middle East & Africa by Country
- 8.7.4. Saudi Arabia
- 8.7.5. UAE
- 8.7.6. Israel
- 8.7.7. South Africa
- 8.7.8. Rest Of Middle East And Africa

9 . COMPETITIVE LANDSCAPE OF THE MULTIPLE MYELOMA THERAPEUTICS COMPANIES

9.1. Multiple Myeloma Therapeutics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF MULTIPLE MYELOMA THERAPEUTICS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Janssen Biotech, Inc.
- 10.3.1. Company Overview
- 10.3.2. Financials
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Bristol-Myers Squibb
- 10.4.1. Company Overview
- 10.4.2. Financials
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Novartis AG
- 10.5.1. Company Overview
- 10.5.2. Financials
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Bristol-Myers Squibb Company
- 10.6.1. Company Overview
- 10.6.2. Financials
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Millennium Pharmaceuticals
- 10.7.1. Company Overview
- 10.7.2. Financials
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Celgene Corporation
- 10.8.1. Company Overview
- 10.8.2. Financials
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Kesios Therapeutics Limited
- 10.9.1. Company Overview
- 10.9.2. Financials
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Amgene, Inc.
- 10.10.1. Company Overview
- 10.10.2. Financials
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Genzyme Corporation
- 10.11.1. Company Overview
- 10.11.2. Financials
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Juno Therapeutics
- 10.12.1. Company Overview
- 10.12.2. Financials
- 10.12.3. Products
- 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies